Anti-Human IL 12/23 (Briakinumab) - HRP
Catalogue Number: 12-8073-ABO
| Manufacturer: | Abeomics |
| Type: | Recombinant Monoclonal |
| Alias: | IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ug |
| Host name: | Human |
| Clone: | ABT-874 |
| Isotype: | IgG1, lambda |
| Immunogen: | This antibody was produced by phage display technology. |
| Application: | ELISA |
Description
Description: Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only. Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23alpha to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
Additional Text
Antibody Clonality
Monoclonal
Application Notes
The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.ELISA
12-8073 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations